H. Silberman

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
H R Silberman, H Silberman, H. Silberman, Howard Silberman
Publication record
60 papers · 2,306 citations · H-index 26

PAPERS

Review of next generation sequencing outcomes in patients with metastatic breast cancer.
20170 citationsauthor #7
The role of F-18 FDG PET/CT and breast MRI in the management of breast cancer.
20160 citationsauthor #3
Modified Bi‐Rads Scoring of Breast Imaging Findings Improves Clinical Judgment
20151 citationsauthor #1
Update and Review on the Surgical Management of Primary Cutaneous Melanoma
201415 citationsauthor #5
Value of routine staging imaging studies (RSIS) for patients with stage III breast cancer (BC).
20140 citationsauthor #10
Image of the month-quiz case. Diagnosis: primary adenocarcinoma.
20120 citationsauthor #2
Principles and practice of surgical oncology : multidisciplinary approach to difficult problems
201013 citationsauthor #1
Comprar Principles and Practice of Surgical Oncology | Allan W. Silberman MD, PhD | 9780781765466 | Lippincott Williams & Wilkins
20090 citationsauthor #2
REEVALUATION OF VENOUS INFUSION OF 5-FU , PHARMACOKINETICS Table 1 Primary tumor diagnosis No . Adenocarcinoma of unknown origin Bladder carcinoma Breast carcinoma Colorectal carcinoma Renal carcinoma Adenocarcinoma of lung Prostatic carcinoma Osteogenic sarcoma Gastric carcinoma
20060 citationsauthor #4
Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast.
200672 citationsauthor #7
Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast.
200669 citationsauthor #8
Perioperative adjunctive treatment in the management of operable gastric cancer
200511 citationsauthor #1
Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins.
2005112 citationsauthor #8
Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast.
200457 citationsauthor #6
MammoSite radiation therapy system.
200327 citationsauthor #7
Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer.
200293 citationsauthor #2
Surgical Oncology: Multidisciplinary Approach to Difficult Problems
200210 citationsauthor #2
Breast-conserving therapy for ductal carcinoma in situ: a 20-year experience with excision plus radiation therapy.
200226 citationsauthor #3
Breast Cancer After Augmentation Mammoplasty
200167 citationsauthor #2
Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2′-deoxyuridine and leucovorin
20015 citationsauthor #5
Palpable Breast Cancers Are Inherently Different From Nonpalpable Breast Cancers
200171 citationsauthor #2
Preoperative Paclitaxel and Radiotherapy for Locally Advanced Breast Cancer: Surgical Aspects
200036 citationsauthor #2
Edosonography of Rectal Cancer
19990 citationsauthor #3
The Breast Biopsy Paradigm Shifts Once Again
19998 citationsauthor #2
Preoperative 5-fluorouracil and radiation therapy for locally advanced breast cancer.
199733 citationsauthor #3
Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy.
199765 citationsauthor #6
Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy
1997112 citationsauthor #10
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
1996366 citationsauthor #9
Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial.
1995131 citationsauthor #9
Left atrial metastasis from hepatocellular carcinoma: a case report.
199415 citationsauthor #3
Comparative study of infections complications of different types of chronic central venous access devices
199432 citationsauthor #5
Chronic venous access in patients with cancer selective use of the saphenous vein
199315 citationsauthor #2
Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program.
1992109 citationsauthor #2
Absorbable versus permanent mesh in abdominal operations.
1989143 citationsauthor #2
Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics.
198845 citationsauthor #4
Approach to oncologic emergencies in the elderly.
19874 citationsauthor #2
Reply to Letter from Drs. Kassum and Cote
19871 citationsauthor #2
Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
19872 citationsauthor #2
Aggressive management of cholecystitis during pregnancy.
1987115 citationsauthor #3
Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
19868 citationsauthor #4
Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
198633 citationsauthor #4
Weekly mitoxantrone therapy for refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
19864 citationsauthor #4
The role of preoperative parenteral nutrition in cancer patients
198518 citationsauthor #1
Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial.
198543 citationsauthor #5
Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma
198432 citationsauthor #2
Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma.
198415 citationsauthor #2
Effects of Age on Responses to Treatment and Survival of Patients with Multiple Myeloma
198325 citationsauthor #2
Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model.
19811 citationsauthor #3
Dosage of corticosteroids in renal allograft rejection.
19817 citationsauthor #1
Leiomyosarcoma of the gastrointestinal tract: Should we consider metastasis to regional lymph nodes?
198014 citationsauthor #2
Management of Crohn's disease involving the duodenum, including duodenal cutaneous fistula.
198032 citationsauthor #3
Hyperalimentation in patients with cancer.
19807 citationsauthor #1
Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma.
197937 citationsauthor #2
Leiomyosarcomas of the small intestine
197922 citationsauthor #2
Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma.
19775 citationsauthor #2
Renal failure and the surgeon.
197712 citationsauthor #1
Oral methyl CCNU (MeCCNU) and prednisone (P) in previously treated multiple myeloma (MM)
19760 citationsauthor #2
Gastric aneurysms: unusual lesions with lethal potential.
197516 citationsauthor #1
Neoplasms of the Small Bowel
197484 citationsauthor #1
RÖNTGEN VISUALIZATION OF THE PAROTID GLAND BY MEANS OF LIPIODOL INJECTION
193210 citationsauthor #2

TIMELINE

1932 10 citations

1974 84 citations

1975 16 citations

1976 0 citations

1977 17 citations

1979 59 citations

1980 53 citations

1981 8 citations

1983 25 citations

1984 47 citations

1985 61 citations

1986 45 citations

1987 122 citations

1988 45 citations

1989 143 citations

1992 109 citations

1993 15 citations

1994 47 citations

1995 131 citations

1996 366 citations

1997 210 citations

1999 8 citations

2000 36 citations

2001 143 citations

2002 129 citations

2003 27 citations

2004 57 citations

2005 123 citations

2006 141 citations

2009 0 citations

2010 13 citations

2012 0 citations

2014 15 citations

2015 1 citations

2016 0 citations

2017 0 citations

H. Silberman

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT